Lexeo Therapeutics (LXEO) Net Cash Flow (2022 - 2026)

Lexeo Therapeutics has reported Net Cash Flow for 5 years, with the latest figure at $8.8 million in Q1 2026.

• Quarterly Net Cash Flow rose 243.62% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.9 million (up 125.79% YoY) and the FY2025 annual result came in at $28.0 million, up 132.37% from the prior year.
• Net Cash Flow eased to $8.8 million in Q1 2026 per LXEO's latest filing, from $22.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $86.0 million in Q4 2023 and troughed at -$122.0 million in Q4 2024.
• A 5-year average of -$1.6 million and a median of -$8.1 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow soared 611.58% in 2023, then sank 241.84% in 2024.
• Over 5 years, Net Cash Flow stood at -$16.8 million in 2022, then jumped by 611.58% to $86.0 million in 2023, then tumbled by 241.84% to -$122.0 million in 2024, then jumped by 118.04% to $22.0 million in 2025, then sank by 60.15% to $8.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $8.8 million, $22.0 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.